Arrowhead Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Christopher R. Anzalone
- Full Time Employees
- 711
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 177 East Colorado Boulevard Pasadena CA United States of America 91105
- IPO Date
- Dec 16, 1993
- CIK
- 0000879407
- Website
- arrowheadpharma.com
- Similar Companies
- Business
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) develops RNA interference (RNAi) therapeutics that silence genes causing intractable diseases using its proprietary Targeted RNAi Molecule (TRiM™) platform; the company's pipeline includes approximately 20 investigational medicines in clinical development across cardiometabolic, pulmonary, liver, neuromuscular, central nervous system, and complement-mediated disease areas, featuring lead candidates such as plozasiran (ARO-APOC3) for severe hypertriglyceridemia and familial chylomicronemia syndrome, zodasiran (ARO-ANG3) for mixed dyslipidemia and homozygous familial hypercholesterolemia, fazirsiran (ARO-AAT) for alpha-1 antitrypsin deficiency-associated liver disease, ARO-C3 for complement-mediated diseases like IgA nephropathy, ARO-MUC5AC and ARO-RAGE for muco-obstructive and inflammatory lung diseases, ARO-HBV for hepatitis B, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and others targeting conditions including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis. Founded in 2003 and headquartered in Pasadena, California, with research and development facilities in Madison and Verona, Wisconsin, and San Diego, California, Arrowhead operates primarily in the United States while advancing partnered and wholly owned programs globally through collaborations with major pharmaceutical companies. Recent developments include a November 2024 global license and collaboration agreement with Sarepta Therapeutics covering multiple clinical and preclinical programs in rare genetic diseases of muscle, CNS, and lungs, providing Arrowhead with $500 million upfront cash, $325 million in equity investment, and potential milestones exceeding $2.7 billion, alongside a $200 million milestone payment from Sarepta in 2025 for progress in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy; the company also maintains ongoing partnerships with GlaxoSmithKline, Takeda, Janssen, Amgen, Horizon Therapeutics, and others, reported FDA approval for its first product plozasiran (branded Redemplo) with a potential commercial launch in 2025 pending final review, and projects cash runway extension into 2028 supported by substantial collaboration revenue of $240.6 million for fiscal year 2024.
Company News
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT Study
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Breaks Below 200 Day Moving Average – Here’s Why
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress
Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Benjamin Edwards Inc. Makes New $721,000 Investment in Arrowhead Pharmaceuticals, Inc. $ARWR
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript